What this means
This is a plan for a study that has not started enrolling people yet. It will check whether a treatment is safe and easy to tolerate, not whether it works.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 50–75 · About 21 adults in a planned human trial
- Where
- 1 site
The science
- Registered title
- aKLmRNA-mediated Protein Replacement Therapy
- Trial ID
- NCT07544420 ↗
- Phase
- PHASE 1
- Study type
- interventional
- Conditions
- Aging
- What is tested
- aKLmRNA (AKL003), Placebo
- Sponsor
- Klothea Bio Inc
- Ages
- 50 Years to 75 Years
- Dates
- First posted Apr 22, 2026 · updated Apr 22, 2026
Registry summary
This is a Phase 1b randomized, double-blind, placebo-controlled study to assess the safety and tolerability of a proprietary aKLmRNA formulated in lipid nanoparticles. Approximately 21 subjects will be enrolled.
Each subject will receive a total of two injections during the study. The cohort will consist of approximately 21 subjects, with each receiving 0.5 mg aKLmRNA (AKL003) or placebo. Subjects will be randomized in a 2:1 ratio (active treatment:placebo). The placebo will be saline, matching the active treatment in both appearance and volume.
Sites (1)
- GARM, Roatán, Bay Islands, Honduras